$5.30
7.02% today
NYSE, Apr 04, 08:50 pm CET
ISIN
US37611X1000
Symbol
DNA

Ginkgo Bioworks Stock price

$5.70
-2.31 28.84% 1M
-2.42 29.80% 6M
-4.12 41.96% YTD
-37.90 86.93% 1Y
-159.50 96.55% 3Y
-399.10 98.59% 5Y
-399.10 98.59% 10Y
NYSE, Closing price Thu, Apr 03 2025
-0.26 4.36%
ISIN
US37611X1000
Symbol
DNA
Sector

Key metrics

Market capitalization $313.69m
Enterprise Value $214.01m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.94
P/S ratio (TTM) P/S ratio 1.38
P/B ratio (TTM) P/B ratio 0.41
Revenue growth (TTM) Revenue growth -9.71%
Revenue (TTM) Revenue $227.04m
EBIT (operating result TTM) EBIT $-462.53m
Free Cash Flow (TTM) Free Cash Flow $-382.13m
Cash position $567.41m
EPS (TTM) EPS $-10.62
P/E forward negative
P/S forward 1.80
EV/Sales forward 1.23
Short interest 29.43%
Show more

Is Ginkgo Bioworks a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Ginkgo Bioworks Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Ginkgo Bioworks forecast:

1x Buy
17%
1x Hold
17%
4x Sell
67%

Analyst Opinions

6 Analysts have issued a Ginkgo Bioworks forecast:

Buy
17%
Hold
17%
Sell
67%

Financial data from Ginkgo Bioworks

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
227 227
10% 10%
100%
- Direct Costs 103 103
18% 18%
45%
124 124
2% 2%
55%
- Selling and Administrative Expenses 158 158
37% 37%
70%
- Research and Development Expense 366 366
29% 29%
161%
-400 -400
37% 37%
-176%
- Depreciation and Amortization 63 63
34% 34%
28%
EBIT (Operating Income) EBIT -463 -463
37% 37%
-204%
Net Profit -547 -547
39% 39%
-241%

In millions USD.

Don't miss a Thing! We will send you all news about Ginkgo Bioworks directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ginkgo Bioworks Stock News

Neutral
Business Wire
one day ago
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Plex Research is partnering with Ginkgo Bioworks to use AI to deepen understanding of the mechanisms of action of existing drugs.
Negative
Seeking Alpha
about one month ago
Ginkgo Bioworks missed Q4 revenue estimates and issued extremely weak 2025 revenue guidance. Despite improving losses and cash burn, financial flexibility is decreasing, with cash reserves dropping significantly over the past year. The company's valuation is low, but declining revenues and high stock-based compensation pose risks.
Negative
Seeking Alpha
about one month ago
Ginkgo Bioworks' restructuring has resulted in a dramatic reduction in cash burn in recent quarters. Ginkgo remains a long way from breakeven though and growth is expected to be poor in 2025. Unless Ginkgo can demonstrate continuous progress in 2025, its stock is likely to remain under pressure due to its shrinking cash runway.
More Ginkgo Bioworks News

Company Profile

Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform is market agnostic and enables biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. It operates through the Cell Programming/Foundry, and Biosecurity segments. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Head office United States
CEO Jason Kelly
Employees 834
Founded 2008
Website www.ginkgo.bio

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today